Cite
HARVARD Citation
Carvelli, J. et al. (2022). Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*. Critical care medicine. 50 (12), pp. 1788-1798. [Online].